Journal Article

Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial

Hughes, Victoria, Waller, David A, Rintoul, Robert C, Fox-Rushby, Julia A, Coonar, Aman S, Bennett, Maxine, Ritchie, Andrew J, Sharples, Linda D, Edwards, John G, Lovato, Eleonora

2014

Overview

Malignant pleural mesothelioma incidence continues to rise, with few available evidence-based therapeutic options. Results of previous non-randomised studies suggested that video-assisted thoracoscopic partial pleurectomy (VAT-PP) might improve symptom control and survival. We aimed to compare efficacy in terms of overall survival, and cost, of VAT-PP and talc pleurodesis in patients with malignant pleural mesothelioma. We undertook an open-label, parallel-group, randomised, controlled trial in patients aged 18 years or older with any subtype of confirmed or suspected mesothelioma with pleural effusion, recruited from 12 hospitals in the UK. Eligible patients were randomly assigned (1:1) to either VAT-PP or talc pleurodesis by computer-generated random numbers, stratified by European Organisation for Research and Treatment of Cancer risk category (high vs low). The primary outcome was overall survival at 1 year, analysed by intention to treat (all patients randomly assigned to a treatment group with a final diagnosis of mesothelioma). This trial is registered with ClinicalTrials.gov, number NCT00821860. Between Oct 24, 2003, and Jan 24, 2012, we randomly assigned 196 patients, of whom 175 (88 assigned to talc pleurodesis, 87 assigned to VAT-PP) had confirmed mesothelioma. Overall survival at 1 year was 52% (95% CI 41–62) in the VAT-PP group and 57% (46–66) in the talc pleurodesis group (hazard ratio 1·04 [95% CI 0·76–1·42]; p=0·81). Surgical complications were significantly more common after VAT-PP than after talc pleurodesis, occurring in 24 (31%) of 78 patients who completed VAT-PP versus ten (14%) of 73 patients who completed talc pleurodesis (p=0·019), as were respiratory complications (19 [24%] vs 11 [15%]; p=0·22) and air-leak beyond 10 days (five [6%] vs one [1%]; p=0·21), although not significantly so. Median hospital stay was longer at 7 days (IQR 5–11) in patients who received VAT-PP compared with 3 days (2–5) for those who received talc pleurodesis (p<0·0001). VAT-PP is not recommended to improve overall survival in patients with pleural effusion due to malignant pleural mesothelioma, and talc pleurodesis might be preferable considering the fewer complications and shorter hospital stay associated with this treatment. BUPA Foundation.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Aged / Biological and medical sciences / Biopsy / Bronchoscopy / Cancer / Cancer therapies / Chemotherapy / Costs / Costs and Cost Analysis / Drug therapy / Endoscopy / Female / General aspects / Health risks / Hospice care / Humans / Internal Medicine / Investigative techniques, diagnostic techniques (general aspects) / Kaplan-Meier Estimate / Lung Neoplasms - economics / Lung Neoplasms - therapy / Male / Medical sciences / Mesothelioma / Mesothelioma - economics / Mesothelioma - therapy / Mesothelioma, Malignant / Miscellaneous / Mortality / Ostomy / Pleural Neoplasms - economics / Pleural Neoplasms - mortality / Pleural Neoplasms - therapy / Pleurodesis - economics / Pleurodesis - methods / Pleurodesis - mortality / Public health. Hygiene / Public health. Hygiene-occupational medicine / Quality-Adjusted Life Years / Radiation therapy / Studies / Survival / Talc - administration & dosage / Talc - economics / Thoracic Surgery, Video-Assisted - economics / Thoracic Surgery, Video-Assisted - methods / Thoracic Surgery, Video-Assisted - mortality / Treatment Outcome